Evidence map›Paper›PMID 40868245›Full record

ArticleBiomedicines2025

Bioequivalence and Pharmacokinetics of Low-Dose Anagrelide 0.5 mg Capsules in Healthy Volunteers.

Ahmet Inal, Zafer Sezer, Onur Pinarbasli, Burcu Bulut, Martin Reinsch, Wolfgang Martin, Mumtaz M Mazicioglu, Selma Alime Koru

Abstract read
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmet InalDepartment of Pharmacology, Hakan Cetinsaya Good Clinical Practice and Research Center, Erciyes University, 38039 Kayseri, Türkiye.ORCID 0000-0002-5917-3729
Zafer SezerDepartment of Pharmacology, Hakan Cetinsaya Good Clinical Practice and Research Center, Erciyes University, 38039 Kayseri, Türkiye.
Onur PinarbasliILKO Pharmaceuticals, 06800 Ankara, Turkey.ORCID 0000-0001-7091-683X
Burcu BulutILKO Pharmaceuticals, 06800 Ankara, Turkey.
Martin ReinschAnalytisches Zentrum Biopharm GmbH, 12681 Berlin, Germany.ORCID 0009-0009-2643-1398
Wolfgang MartinPharmakin Consulting Services UG, 89233 Neu-Ulm, Germany.ORCID 0009-0004-0862-9396
Mumtaz M MaziciogluDepartment of Family Medicine, Hakan Cetinsaya Good Clinical Practice and Research Center, Erciyes University, 38039 Kayseri, Türkiye.ORCID 0000-0002-6458-2906
Selma Alime KoruIDEAL Biological Products and Pharmaceutical Consultancy Training Ltd. Sti., 06530 Ankara, Türkiye.

Funding

This study was supported by ILKO Pharmaceuticals, Turkiye 66175679-514.06.01-E.45591
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anagrelidebioequivalencecrossover studyfastinghealthy volunteersLC-MS/MSpharmacokinetics

Identifiers

PMID40868245
PMCPMC12383776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.